Payment overview · 2025
General Payments
$81.73
4 reported records · 2 companies
Healthcare provider profile · identity verified
Steven Sherman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WELLINGTON, FL · NPI 1003998345
Verified facts
What the public records show
CMS Open Payments records show Steven Sherman, MD received $81.73 in general payments during 2025 across 4 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 73.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $60.04 | 73.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.69 | 26.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $81.73 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $60.04 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 797 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 758 | 187 |
| Levothyroxine Sodium | Levothyroxine Sodium | 584 | 114 |
| Gabapentin | Gabapentin | 543 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 481 | 127 |
| Tamsulosin Hcl | Tamsulosin Hcl | 366 | 91 |
| Losartan Potassium | Losartan Potassium | 334 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 328 | 93 |
| Furosemide | Furosemide | 284 | 89 |
| Famotidine | Famotidine | 278 | 58 |
| Metformin Hcl | Metformin Hcl | 265 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 79 |
| Escitalopram Oxalate | Escitalopram Oxalate | 258 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 249 | 60 |
| Donepezil Hcl | Donepezil Hcl | 230 | 48 |
| Potassium Chloride | Potassium Chloride | 229 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 228 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 203 | 57 |
| Trazodone Hcl | Trazodone Hcl | 191 | 46 |
| Carvedilol | Carvedilol | 187 | 60 |
| Quetiapine Fumarate | Quetiapine Fumarate | 176 | 43 |
| Memantine Hcl | Memantine Hcl | 155 | 25 |
| Sertraline Hcl | Sertraline Hcl | 148 | 41 |
| Finasteride | Finasteride | 141 | 30 |
| Xarelto | Rivaroxaban | 139 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 32 |
| Mirtazapine | Mirtazapine | 134 | 41 |
| Levetiracetam | Levetiracetam | 129 | 24 |
| Midodrine Hcl | Midodrine Hcl | 125 | 36 |
| Divalproex Sodium | Divalproex Sodium | 122 | 21 |
| Entresto | Sacubitril/Valsartan | 122 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 120 | 35 |
| Lisinopril | Lisinopril | 118 | 40 |
| Amiodarone Hcl | Amiodarone Hcl | 113 | 23 |
| Omeprazole | Omeprazole | 111 | 35 |
| Simvastatin | Simvastatin | 110 | 24 |
| Spironolactone | Spironolactone | 101 | 19 |
| Latanoprost | Latanoprost | 97 | 36 |
| Nifedipine Er | Nifedipine | 91 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 18 |
| Januvia | Sitagliptin Phosphate | 78 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 77 | 15 |
| Metformin Hcl Er | Metformin Hcl | 77 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 76 | 34 |
| Montelukast Sodium | Montelukast Sodium | 76 | 19 |
| Allopurinol | Allopurinol | 75 | 13 |
| Jardiance | Empagliflozin | 72 | 16 |
| Mupirocin | Mupirocin | 71 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 56 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 55 | 19 |
| Baclofen | Baclofen | 54 | 13 |
| Nystatin | Nystatin | 54 | 24 |
| Sodium Chloride | 0.9 % Sodium Chloride | 54 | 30 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 53 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 26 |
| Ezetimibe | Ezetimibe | 51 | 18 |
| Glipizide | Glipizide | 50 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 49 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 20 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 48 | suppressed |
| Atenolol | Atenolol | 47 | 13 |
| Risperidone | Risperidone | 47 | 12 |
| Timolol Maleate | Timolol Maleate | 47 | suppressed |
| Torsemide | Torsemide | 47 | suppressed |
| Prednisone | Prednisone | 46 | 16 |
| Budesonide | Budesonide | 45 | 12 |
| Buspirone Hcl | Buspirone Hcl | 45 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 14 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 42 | 15 |
| Vancomycin Hcl | Vancomycin Hcl | 42 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 18 |
| Methenamine Hippurate | Methenamine Hippurate | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 37 | 20 |
| Sevelamer Carbonate | Sevelamer Carbonate | 37 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 36 | 17 |
| Movantik | Naloxegol Oxalate | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 26 |
| Azithromycin | Azithromycin | 34 | 22 |
| Cephalexin | Cephalexin | 34 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 26 |
| Valsartan | Valsartan | 34 | 15 |
| Bumetanide | Bumetanide | 33 | 14 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Rivastigmine | Rivastigmine | 31 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 30 | suppressed |
| Lactulose | Lactulose | 30 | 15 |
| Silodosin | Silodosin | 30 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | 12 |
| Digoxin | Digoxin | 28 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 28 | suppressed |
| Permethrin | Permethrin | 28 | 15 |
| Calcitriol | Calcitriol | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Restasis | Cyclosporine | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Octreotide Acetate | Octreotide Acetate | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Insulin Lispro | Insulin Lispro | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Multaq | Dronedarone Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | 21 |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 17 |
| Primidone | Primidone | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 17 |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 16 |
| Arformoterol Tartrate | Arformoterol Tartrate | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Ivermectin | Ivermectin | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | 17 |
| Acetazolamide | Acetazolamide | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | 11 |
| Tradjenta | Linagliptin | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Alprazolam | Alprazolam | 17 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Glucagon Emergency Kit | Glucagon | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Fiasp | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Restasis Multidose | Cyclosporine | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Daptomycin | Daptomycin | 11 | suppressed |
| Epogen | Epoetin Alfa | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $81.73 · 4 records | Otsuka America Pharmaceutical, Inc. | MOUNJARO, REXULTI, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error